Dynavax Technologies Corporation (Nasdaq:DVAX) announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax"s first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008.
buy viagra
Every hour of the day children are inactive adds three minutes to the time it takes them to fall asleep, finds research published ahead of print in Archives of Disease in Childhood.
A new study by a University of Arizona professor shows employee involvement programs that executives adopt to increase efficiency also end up improving their record on diversity.